CD4+, IL17 and Foxp3 Expression in Different pTNM Stages of Operable Non-small Cell Lung Cancer and Effects on Disease Prognosis

  • Zhang, Guo-Qing (Lung Cancer Treatment Center, Tumor Hospital affiliated to Xinjiang Medical University) ;
  • Han, Feng (Lung Cancer Treatment Center, Tumor Hospital affiliated to Xinjiang Medical University) ;
  • Fang, Xin-Zhi (Lung Cancer Treatment Center, Tumor Hospital affiliated to Xinjiang Medical University) ;
  • Ma, Xiao-Mei (Lung Cancer Treatment Center, Tumor Hospital affiliated to Xinjiang Medical University)
  • Published : 2012.08.31


Objective: To investigate the effects of $CD4^+$, IL17 and Foxp3 expression on prognosis of operable non-small cell lung cancer (NSCLC) with different pTNM stages. Methods: Expression of $CD4^+$, IL17 and Foxp3 in 102 cases of NSCLC tissues and adjacent cancer tissues was detected by immunohistochemistry and associations with prognosis with different pTNM stages were analyzed. The Chi-square test was used to compare count data. Survival differences were evaluated by Kaplan-Meier single factor analysis and the COX regression model was used to analyze the relationship between influential factors and the disease prognosis. The significance level was ${\alpha}$=0.05. Results: Expression of CD4, IL-17 and Foxp3 significantly varied in different pTNM stages of NSCLC tissues (P < 0.05). The same was true for CD4 expression (P < 0.05). The median survival time (MST) in the positive CD4 expression group was evidently higher than that in the negative group (25.8/23.9 months). Compared with stage III, the MST difference of stages I and II in the positive CD4 expression group were statistically significant (P < 0.05). The MST in positive IL-17 and Foxp3 expression groups was obviously lower than that in the corresponding negative group (P < 0.05) (25.6/35.1 months and 24/35.3 months, respectively). There was a significant difference of MST between any two of three stages of positive IL-17 expression group (P < 0.05), and it was the same with positive Foxp3 expression group. TNM stage, negative CD4 expression, and positive IL-17 and Foxp3 expression were the main risk factors for the prognosis of NSCLC. Conclusion: Surgical prognosis of NSCLC can be better assessed by the combination of clinical staging and expression of IL17 and Foxp3.


  1. Beyer M, Schultze JL (2009). Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des, 15, 1879-92.
  2. DeNardo DG, Barreto JB, Andreu P, et al (2009). CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 16, 91-102.
  3. Dong C (2008). Th17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol, 8, 337-48.
  4. Feng L, Jia X, Zhu M, et al (2010). Chemoprevention by Prunella vulgaris L. extract of non-small cell lung cancer via promoting apoptosis and regulating the cell cycle. Asian Pac J Cancer Prev, 11, 1355-8.
  5. Gray CP, Arosio P, Hersey P (2003). Association of increased levels of heavy-chain ferritin with increased $CD4^{+} CD25^{+}$ regulatory T cell levels in patients with melanoma. Clin Cancer Res, 9, 2551-9.
  6. Greenberg PD, Kern DE, Cheever MA (1985). Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+, 2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med, 161, 1122-34.
  7. Hiraoka N, OnozatoK, KosugeT, et al (2006). Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res, 12, 5423-34.
  8. Huang YH, Zozulya AL, Weidenfeller C, Schwab N, Wiendl H (2009). T cell supp ression by naturally occurring HLA2G2exp ressing regulatory $CD4^{+}$ T cells is IL-10- dependent and reversible. J Leu koc Biol, 86, 273-81.
  9. Hunder NN, Wallen H, Cao J, et al (2008). Treatment of metastatic melanoma with autologous $CD4^{+}$ T cells against NY-ESO-1. N Engl J Med, 358, 2698-703.
  10. Kobayashi N, Hiraoka N, Yamagami W, et al (2007). FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin CancerRes, 13, 902-11.
  11. Kono K, Kawaida H, TakahashiA, et al (2006). CD4(+)CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother, 55, 1064-71.
  12. Kornt, Bettell IE, Oukka M, et al (2009). IL-17 and Th17 cells. Annu Rev Imm unol, 27, 485-517.
  13. Larmonier N, Marron M, Zeng Y, et al (2007). Tumor-derived $CD4^{+}CD25^{+}$regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.Cancer Immunol Immunothe, 56, 48-59.
  14. Le Gouvello S, Bastuji-Garin S, Aloulou N, et al (2008). High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut, 57, 772-9.
  15. Liu Z, Kim JH, Falo LD Jr, You Z (2009). Tumor regulatory T cells potently abrogate antitumor immunity [J]. J Immunol, 182, 6160-7.
  16. Park H, Li Z, Yang XO, et a1 (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat immunol, 6, 1133-41.
  17. Sallusto F et al (2009). Heterogeneity of $CD4^{+}$memory T cells: functional modules for tailored immunity. Eur J Immunol, 39, 2076-82
  18. Tian T, Zhang Z, Fei F, et al (2011). Up-regulation of GTSE1 lacks a relationship with clinical data in lung cancer. Asian Pac J Cancer Prev, 12, 2039-43.
  19. Veldhoen M, Hocking RJ, Atkins CJ, et a1 (2009). TGFbeta in the c geneity of $CD4^{+}$memory T cells: functional modules for tailored immunity. Eur J Immunol, 39, 2076-82.
  20. Wan YY, Flavell RA (2007).Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature, 445, 766-70.
  21. Wieder T, Braumüller H, Kneilling M, et al (2008). T cell mediated help against tumors. Cell Cycle, 7, 2974-7
  22. Williams LM, Rudensky AY (2007). Maintenance of the Foxp3- dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol, 8, 277-84.
  23. Winter H, van den Engel NK, Rüttinger D, et al (2007). Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines. J Transl Med, 5, 56.
  24. Woo EY, Chu CS, GoletzTJ, et al (2001). Regulatory CD4(+) CD25(+) T cells in tumors from patients with early-stage NSCLC and late-stage ovarian cancer. CancerRes, 61, 4766-72.
  25. Zhang B, Rong G, Wei H, et al (2008). The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun, 374, 533-7.
  26. Zhang JP, Yan J, Xu J, et al (2009). Increased intratumoral IL-17 producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol, 50, 980-9.

Cited by

  1. Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF-1α expression in vivo vol.10, pp.2, 2014,
  2. Interleukin-8 and Interleukin-17 for Cancer vol.32, pp.5, 2014,
  3. Expression of Granulysin and FOXP3 in Cutaneous T Cell Lymphoma and Sézary Syndrome vol.16, pp.13, 2015,
  4. PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC vol.11, pp.4, 2016,
  5. The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients vol.12, pp.9, 2017,
  6. Strong expression of interleukin-17 is associated with higher histologic grades in canine mammary carcinoma vol.26, pp.2, 2017,
  7. Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans vol.66, pp.2, 2017,
  8. Prognostic Value of Serum IL-17 and VEGF Levels in Small Cell Lung Cancer vol.30, pp.4, 2015,